A De Novo Strategy To Improve Pharmacokinetics of Proteins from mRNA Therapeutics via Zwitterionic Polypeptide Fusion.
J Am Chem Soc
; 146(31): 21245-21249, 2024 Aug 07.
Article
en En
| MEDLINE
| ID: mdl-39074299
ABSTRACT
Achieving therapeutic efficacy in protein replacement therapies requires sustaining pharmacokinetic (PK) profiles, while maintaining the bioactivity of circulating proteins. This is often achieved via PEGylation in protein-based therapies, but it remains challenging for proteins produced in vivo in mRNA-based therapies due to the lack of a suitable post-translational modification method. To address this issue, we integrated a genetically encoded zwitterionic polypeptide, EKP, into mRNA constructs to enhance the PK properties of product proteins. Composed of alternating glutamic acid (E), lysine (K), and proline (P), EKP exhibits unique superhydrophilic properties and low immunogenicity. Our results demonstrate that EKP fusion significantly extends the circulation half-life of proteins expressed from mRNA while preserving their bioactivity using human interferon alpha and Neoleukin-2/15 as examples. This EKP fusion technology offers a new approach to overcoming the current limitations in mRNA therapeutics and has the potential to significantly advance the development of mRNA-based protein replacement therapy.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Péptidos
/
ARN Mensajero
Límite:
Animals
/
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article